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Background: Non-obstructive coronary artery disease (CAD) is often thought to confer less risk for adverse outcomes than obstructive CAD in 
myocardial infarction (MI) patients. However, the frequency and outcomes of non-obstructive CAD at the time of MI have not been compared with 
those of obstructive CAD.
Methods:  In a national cohort of MI patients hospitalized between 2005 and 2008, we compared 1-year mortality and re-hospitalization rates 
between patients with non-obstructive and obstructive CAD. Non-obstructive CAD was defined as all coronary plaques <70% (<50% left main). 
Patients with normal coronaries (no plaque >20%) were excluded. Site-stratified proportional hazards regression assessed the association between 
non-obstructive CAD and mortality/re-hospitalization adjusting for patient, presentation, and site characteristics.
Results:  Among 3830 post-MI patients undergoing coronary angiography, 207 (5.4%) had non-obstructive CAD. These patients were more 
likely to be female, non-white, and present with an NSTEMI. They were less likely to receive antiplatelets or IIb/IIIa inhibitors on presentation and 
plavix or beta-blockers on discharge. One year after MI, mortality (7.0% for non-obstructive CAD and 5.1% for obstructive CAD, p-value 0.24) and 
re-hospitalization (31.9% for non-obstructive CAD and 30.0% for obstructive CAD, p-value 0.71) rates were similar. After adjustment for patient, 
presentation, and discharge medication factors, mortality (HR 1.15, 95% CI 0.63, 2.11) and re-hospitalization (HR 1.04, 95% CI 0.74, 1.46) rates 
remained similar. Higher rates of secondary prevention medications at discharge were associated with lower mortality rates (HR 0.99 95% CI 0.98, 
1.00).
Conclusions:  While present in only 1 in 20 AMI patients, the 1-year outcomes of non-obstructive CAD patients appear to be similar to those with 
obstructive CAD. In addition, higher rates of secondary prevention medications at discharge were associated with lower mortality. The intensity of 
non-revascularization cardiac treatment should not differ based upon the degree of obstructive CAD found during treatment of an MI.
